CGRP and Migraine Aura: What the Research Shows
Explore the CGRP migraine aura connection: how this protein relates to visual symptoms, cortical spreading depression, and what to track.
Explore the CGRP migraine aura connection: how this protein relates to visual symptoms, cortical spreading depression, and what to track.
The CGRP migraine aura connection is one of the more nuanced areas of current headache research. Most of what people read about calcitonin gene-related peptide (CGRP) focuses on pain and preventive treatments, but the relationship between CGRP and the sensory disturbances that precede or accompany a migraine attack adds another layer worth understanding. This article breaks down what researchers currently know, what remains uncertain, and what information is worth tracking if you experience aura.
Aura refers to transient neurological symptoms that typically develop gradually over five to twenty minutes and resolve within sixty minutes. The most common form is visual: zigzag lines, flickering lights, blind spots, or tunnel vision. Other aura types involve sensory changes (tingling or numbness, usually moving from the hand toward the face), speech difficulties, or less commonly, motor symptoms.
Aura occurs in roughly one-third of people who live with migraine. It can precede the headache phase, overlap with it, or in some cases occur without any headache at all (called migraine with aura without headache, sometimes referred to as ocular migraine in older literature).
If you are unsure whether your pattern qualifies as episodic or chronic migraine, the episodic vs chronic migraine explainer covers the distinction in detail.
The leading explanation for aura is a phenomenon called cortical spreading depression (CSD). This is a slow wave of intense electrical activity that moves across the cortex, followed by a period of suppressed activity. As the wave passes through areas responsible for vision, sensation, or language, it produces the symptoms associated with aura.
CSD is not unique to humans; it has been studied in animal models for decades. In those models, CSD reliably triggers a release of inflammatory signals and activates trigeminal nerve fibers, which are the same pathways central to migraine pain.
CGRP is a neuropeptide released from trigeminal nerve endings. During a migraine attack, CGRP levels in the blood and cerebrospinal fluid rise significantly. This rise is well-documented and is part of why CGRP became a target for both acute and preventive treatments.
The relationship between CGRP and aura is more complicated:
The current thinking is that CSD initiates the aura symptoms directly through its electrical effects, while CGRP contributes to the pain and vascular changes that follow. Whether CGRP plays any role in initiating or sustaining CSD in humans is still under investigation.
For a broader overview of what CGRP is and how it functions in the migraine process, see what is CGRP.
One practical reason to understand aura biology is timing. The gap between aura onset and peak headache pain can be ten to sixty minutes. For people who use time-sensitive acute treatments, recognizing aura early can be clinically useful. Talk with your clinician about whether starting treatment at aura onset makes sense for your situation.
Aura also carries its own clinical considerations. Migraine with aura, particularly in certain populations, is associated with a modestly elevated cardiovascular risk. This is one more reason why keeping an accurate log of your aura frequency, duration, and type matters, not just for migraine management, but for your overall health picture.
Not everyone who has migraine with aura experiences it every attack. Aura frequency can shift over time, sometimes becoming less frequent as people age, sometimes appearing for the first time in adulthood. Tracking whether aura is present or absent per attack, and logging the type and duration, adds meaningful data to your migraine history.
Useful things to note per attack:
The migraine triggers tracking guide walks through how to build a consistent logging habit.
If you are working with a clinician to reduce migraine frequency, aura episodes should be part of what you measure, not just headache days. A reduction in aura frequency, or a change in aura intensity, can be a meaningful signal.
Standard tools like MIDAS and HIT-6 capture headache-related disability but do not specifically account for aura. The MIDAS and HIT-6 explained article covers how these scores work and what they capture. For tracking overall migraine reduction, the migraine reduction calculator can help you quantify change over time.
Most aura resolves within an hour and follows a familiar pattern for the person experiencing it. Symptoms that are sudden in onset (rather than gradually developing), last longer than sixty minutes, involve one-sided weakness, or are the first aura you have ever experienced should be evaluated by a clinician promptly. These features can overlap with other neurological conditions that require different workup.
The Migraine Tracker: CGRP Log lets you record each attack with fields for aura type, duration, and symptom details alongside your usual headache and pain data. Over time, this log gives you a structured record you can share with your clinician to show whether aura patterns are shifting. See how to share your migraine log with your doctor for tips on making that conversation productive.
Tracking is a tool for understanding your pattern, not a substitute for medical evaluation. Only your clinician can interpret your full history and determine whether any change in treatment is appropriate.
Educational, not medical advice. Migraine Tracker: CGRP Log is a personal tracking tool, not a medical device. It does not diagnose, treat, or provide medical advice. Always talk to your clinician.
CGRP does not appear to directly trigger aura. Research suggests aura arises from cortical spreading depression, a wave of electrical activity across the brain. CGRP levels rise during and after this wave, but the relationship is still being studied.
Explore how CGRP migraine hormones estrogen interact to make migraines three times more common in women, and what to track to help your doctor.
Comparing CGRP monoclonal antibodies vs gepants? Learn how each class works, how they differ in use and timing, and what questions to bring to your clinician.
Gepants migraine explained: how oral CGRP receptor blockers work, who they are for, and what questions to bring to your next neurology appointment.